Amphastar Pharmaceuticals AMPH
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Key Insights
Critical company metrics and information
Latest Closing Price
$28.81Market Cap
$1.37 BillionPrice-Earnings Ratio
8.86Total Outstanding Shares
47.65 Million SharesTotal Employees
2,028Dividend
No dividendIPO Date
June 25, 2014SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
11570 sixth street, Rancho cucamonga, CA, 91730Homepage
https://www.amphastar.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $-78.69 Million |
| Net Cash Flow From Operating Activities | $208.23 Million |
| Net Cash Flow, Continuing | $-78.27 Million |
| Net Cash Flow From Financing Activities | $-94.19 Million |
| Exchange Gains/Losses | $-417,000 |
| Net Cash Flow From Operating Activities, Continuing | $208.23 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss Before Equity Method Investments | $188.22 Million |
| Income Tax Expense/Benefit | $28.35 Million |
| Income/Loss From Continuing Operations Before Tax | $187.15 Million |
| Other Operating Expenses | $92.90 Million |
| Benefits Costs and Expenses | $536.40 Million |
| Operating Expenses | $169.09 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $157.31 Million |
| Comprehensive Income/Loss | $157.66 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-410,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $40.02 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $727.68 Million |
| Assets | $1.55 Billion |
| Accounts Payable | $34.09 Million |
| Equity | $727.68 Million |
| Liabilities | $817.50 Million |
| Other Current Liabilities | $95.72 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about AMPH from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.